This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/chemspider/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/pdb/
n30http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/bindingdb/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/pubchem-substance/
n7http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/ontology/sukl/drug/
n29http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00518/identifier/national-drug-code-directory/

Statements

Subject Item
n2:DB00518
rdf:type
n3:Drug
n3:description
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
n3:dosage
n9:271B643F-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17350811 # Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11110097 # Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11343808 # Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8228321
n3:group
approved
n3:halfLife
Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).
n3:indication
For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <i>Taenia solium</i> and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <i>Echinococcus granulosus</i>.
n3:manufacturer
n14:271B643C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00518 n13:DB00518
dcterms:title
Albendazole
adms:identifier
n5:PA164746058 n8:Albendazole n17:C01779 n18:1998 n19:DB00518 n20:50241293 n21:16664 n22:2082 n23:46506472 n24:ALW n25:D00134 n26:0007-5500-40
n3:mechanismOfAction
Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
n3:packager
n14:271B6439-363D-11E5-9242-09173F13E4C5 n14:271B643A-363D-11E5-9242-09173F13E4C5 n14:271B643B-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.
n3:synonym
Ricobendazole Albenza Zentel (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester Rycobendazole Albendazole Albendazol O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate Eskazole Proftril Valbazen Albendazolum 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
n3:toxicity
Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.
n3:mixture
n15:271B6437-363D-11E5-9242-09173F13E4C5 n15:271B6438-363D-11E5-9242-09173F13E4C5 n15:271B6436-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
70% bound to plasma protein
n3:synthesisReference
Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to Smith Kline Corp.
foaf:page
n7:albendazole.html n30:albendazole.htm
n3:IUPAC-Name
n10:271B6444-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B644A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B6449-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B6446-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B6447-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B6448-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B6442-363D-11E5-9242-09173F13E4C5 n10:271B645A-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B6440-363D-11E5-9242-09173F13E4C5 n10:271B6443-363D-11E5-9242-09173F13E4C5 n10:271B645C-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B6441-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:P02CA03
n3:H-Bond-Acceptor-Count
n10:271B6450-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B6451-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B644B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B644C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B644E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B644D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B644F-363D-11E5-9242-09173F13E4C5
n3:absorption
Poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g)
n3:affectedOrganism
Helminthic Microorganisms
n3:casRegistryNumber
54965-21-8
n3:containedIn
n27:271B643D-363D-11E5-9242-09173F13E4C5 n27:271B643E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n10:271B6456-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B6458-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B6459-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B645B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B6455-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B6454-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B6457-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B6445-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n10:271B6452-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B6453-363D-11E5-9242-09173F13E4C5